{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T23:38:24Z","timestamp":1787701104117,"version":"build-2784847793"},"reference-count":59,"publisher":"BMJ","funder":[{"name":"National Health and Medical Research Council of Australia","award":["1066536"],"award-info":[{"award-number":["1066536"]}]},{"name":"National Health and Medical Research Council of Australia","award":["1142976"],"award-info":[{"award-number":["1142976"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"abstract":"<jats:sec><jats:title>Background and aims<\/jats:title><jats:p>Sustained virological suppression and hepatitis B surface antigen (HBsAg) loss have been described after nucleot(s)ide analogue (NA) discontinuation for patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB). We performed a meta-analysis of the clinical outcomes after NA discontinuation for HBeAg-negative CHB.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Studies involving NA cessation in HBeAg-negative CHB individuals with a median follow-up of \u226512 months were included. Participants were HBeAg-negative at the time of NA initiation. Random effects meta-analyses were performed for the following clinical outcomes: (1) virological relapse (VR) at 6 and 12 months; (2) clinical relapse (CR) at 6 and 12 months and (3) HBsAg loss. Effect of other variables was estimated using subgroup analysis and meta-regression. Studies including patients stopping entecavir (ETV) and\/or tenofovir disoproxil fumarate (TDF) were considered separately to studies including patients stopping older generation NA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>N=37 studies met inclusion criteria. Cumulative incidence of VR and CR after stopping ETV\/TDF was 44% and 17% at 6 months and 63% and 35% at 12 months. Similar relapse rates were observed after stopping older NAs. Among patients stopping ETV\/TDF, TDF cessation was associated with increased CR rates at 6 months versus ETV. There was an association between follow-up \u22654 years and HBsAg loss rates when stopping older NAs. Hepatic decompensation and hepatocellular carcinoma were rare but occurred more frequently in studies including cirrhotic individuals.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>VR is common after NA discontinuation, however, CR was only seen in one-third of patients at 12 months. Stopping NA therapy can be followed by HBsAg clearance, and rates are higher with longer follow-up.<\/jats:p><\/jats:sec>","DOI":"10.1136\/gutjnl-2020-323979","type":"journal-article","created":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T17:21:23Z","timestamp":1631035283000},"page":"gutjnl-2020-323979","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":24,"title":["Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis"],"prefix":"10.1136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7158-585X","authenticated-orcid":false,"given":"Samuel Anthony Lachlan","family":"Hall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Vogrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Wawryk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth S","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumar","family":"Visvanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijaya","family":"Sundararajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,9,7]]},"reference":[{"key":"2021090710201303000_gutjnl-2020-323979v1.1","unstructured":"World Health Organisation . Global hepatitis report 2017, 2017."},{"key":"2021090710201303000_gutjnl-2020-323979v1.2","unstructured":"Australian Government Department of Health . 3Rd national hepatitis B strategy 2018-2022, 2018. Available: http:\/\/www.health.gov.au\/internet\/main\/publishing.nsf\/Content\/ohp-bbvs-1\/\/$File\/Hep-B-Third-Nat-Strategy-2018-22.pdf"},{"key":"2021090710201303000_gutjnl-2020-323979v1.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"2021090710201303000_gutjnl-2020-323979v1.4","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.2006.044826"},{"key":"2021090710201303000_gutjnl-2020-323979v1.5","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.05.039"},{"key":"2021090710201303000_gutjnl-2020-323979v1.6","unstructured":"Wells G , Shea B , O\u2019Connell D . Newcastle-Ottawa quality assessment scale cohort studies 2014."},{"key":"2021090710201303000_gutjnl-2020-323979v1.7","unstructured":"Bormann I . DigitizeIt, 2015."},{"key":"2021090710201303000_gutjnl-2020-323979v1.8","doi-asserted-by":"crossref","unstructured":"Hosmer DWL , S.; May S . Applied survival analysis: regression modelling to time to event data. 2nd ed, 2008.","DOI":"10.1002\/9780470258019"},{"key":"2021090710201303000_gutjnl-2020-323979v1.9","doi-asserted-by":"publisher","DOI":"10.1177\/1536867X0800800102"},{"key":"2021090710201303000_gutjnl-2020-323979v1.10","doi-asserted-by":"publisher","DOI":"10.1214\/aoms\/1177729756"},{"key":"2021090710201303000_gutjnl-2020-323979v1.11","doi-asserted-by":"publisher","DOI":"10.2307\/2276774"},{"key":"2021090710201303000_gutjnl-2020-323979v1.12","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/2049-3258-72-39","article-title":"Metaprop: a Stata command to perform meta-analysis of binomial data","volume":"72","author":"Nyaga","year":"2014","journal-title":"Arch Public Health"},{"key":"2021090710201303000_gutjnl-2020-323979v1.13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"2021090710201303000_gutjnl-2020-323979v1.14","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1093\/infdis\/jix690","article-title":"Distinct relapse rates and risk predictors after discontinuing tenofovir and entecavir therapy","volume":"217","author":"Su","year":"2018","journal-title":"J Infect Dis"},{"key":"2021090710201303000_gutjnl-2020-323979v1.15","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jhep.2017.07.012","article-title":"Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study","volume":"67","author":"Berg","year":"2017","journal-title":"J Hepatol"},{"key":"2021090710201303000_gutjnl-2020-323979v1.16","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29640"},{"key":"2021090710201303000_gutjnl-2020-323979v1.17","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-02010-w","article-title":"Incidence and predictors of HBV relapse after cessation of nucleoside analogues in HBeAg-negative patients with HBsAg\u2009\u2264\u2009200\u2009IU\/mL","volume":"7","author":"Yao","year":"2017","journal-title":"Sci Rep"},{"key":"2021090710201303000_gutjnl-2020-323979v1.18","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/cld.728","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"12","author":"Terrault","year":"2018","journal-title":"Clin Liver Dis"},{"key":"2021090710201303000_gutjnl-2020-323979v1.19","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-015-9675-4"},{"key":"2021090710201303000_gutjnl-2020-323979v1.20","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1093\/infdis\/jiy350","article-title":"Contrasting timing of virological relapse after discontinuation of tenofovir or entecavir in hepatitis B E antigen-negative patients","volume":"218","author":"H\u00f6ner Zu Siederdissen","year":"2018","journal-title":"J Infect Dis"},{"key":"2021090710201303000_gutjnl-2020-323979v1.21","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/S0168-8278(20)30674-7","article-title":"A prospective study of nucleot(s)ide analogue discontinuation in non-cirrhotic HBeAg-negative chronic hepatitis B patients: interim analysis at week 48 demonstrates profound reductions of HBsAg associated with ALT flare","volume":"73","author":"Hall","year":"2020","journal-title":"J Hepatol"},{"key":"2021090710201303000_gutjnl-2020-323979v1.22","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3182185276"},{"key":"2021090710201303000_gutjnl-2020-323979v1.23","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/cmi.2010.37","article-title":"Enhancing the antihepatitis B virus immune response by adefovir dipivoxil and entecavir therapies","volume":"8","author":"Jiang","year":"2011","journal-title":"Cell Mol Immunol"},{"key":"2021090710201303000_gutjnl-2020-323979v1.24","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2013-305785"},{"key":"2021090710201303000_gutjnl-2020-323979v1.25","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/liv.14371","article-title":"Will we need novel combinations to cure HBV infection?","volume":"40 Suppl 1","author":"Dusheiko","year":"2020","journal-title":"Liver Int"},{"key":"2021090710201303000_gutjnl-2020-323979v1.26","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-318981"},{"key":"2021090710201303000_gutjnl-2020-323979v1.27","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S2468-1253(18)30308-X","article-title":"Spontaneous loss of surface antigen among adults living with chronic hepatitis B virus infection: a systematic review and pooled meta-analyses","volume":"4","author":"Zhou","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2021090710201303000_gutjnl-2020-323979v1.28","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ijid.2019.07.036","article-title":"Predictors of relapse after cessation of nucleos(t)ide analog treatment in HBeAg-negative chronic hepatitis B patients: A meta-analysis","volume":"86","author":"Liu","year":"2019","journal-title":"Int J Infect Dis"},{"key":"2021090710201303000_gutjnl-2020-323979v1.29","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12908"},{"key":"2021090710201303000_gutjnl-2020-323979v1.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.04.029"},{"key":"2021090710201303000_gutjnl-2020-323979v1.31","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/infdis\/jix025","article-title":"Off-Treatment Hepatitis B Virus (HBV) DNA Levels and the Prediction of Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy in Patients With Chronic Hepatitis B: A Prospective Stop Study","volume":"215","author":"Cao","year":"2017","journal-title":"J Infect Dis"},{"key":"2021090710201303000_gutjnl-2020-323979v1.32","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s00535-010-0354-x","article-title":"Clevudine-induced viral response, associated with continued reduction of HBsAg titer, was durable after the withdrawal of therapy","volume":"46","author":"Lee","year":"2011","journal-title":"J Gastroenterol"},{"key":"2021090710201303000_gutjnl-2020-323979v1.33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2010.06492.x"},{"key":"2021090710201303000_gutjnl-2020-323979v1.34","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.cmi.2017.12.013","article-title":"Long-Term incidence and predictors of hepatitis B surface antigen loss after discontinuing nucleoside analogues in noncirrhotic chronic hepatitis B patients","volume":"24","author":"Chen","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2021090710201303000_gutjnl-2020-323979v1.35","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3350\/cmh.2013.19.3.300","article-title":"Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients","volume":"19","author":"Kim","year":"2013","journal-title":"Clin Mol Hepatol"},{"key":"2021090710201303000_gutjnl-2020-323979v1.36","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/1751-2980.12654","article-title":"Varying 10-year off-treatment responses to nucleos(t)ide analogues in patients with chronic hepatitis B according to their pretreatment hepatitis B e antigen status","volume":"19","author":"Liu","year":"2018","journal-title":"J Dig Dis"},{"key":"2021090710201303000_gutjnl-2020-323979v1.37","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-015-1153-1"},{"key":"2021090710201303000_gutjnl-2020-323979v1.38","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/hep.29497","article-title":"Significance of definitions of relapse after discontinuation of oral antivirals in HBeAg-negative chronic hepatitis B","volume":"68","author":"Papatheodoridis","year":"2018","journal-title":"Hepatology"},{"key":"2021090710201303000_gutjnl-2020-323979v1.39","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1002\/jmv.24715","article-title":"Antiviral response is not sustained after cessation of lamivudine treatment in chronic hepatitis B patients: a 10-year follow-up study","volume":"89","author":"Kang","year":"2017","journal-title":"J Med Virol"},{"key":"2021090710201303000_gutjnl-2020-323979v1.40","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/jvh.12683","article-title":"Hepatitis B surface antigen loss and clinical outcomes between HBeAg-negative cirrhosis patients who discontinued or continued nucleoside analogue therapy","volume":"24","author":"Hung","year":"2017","journal-title":"J Viral Hepat"},{"key":"2021090710201303000_gutjnl-2020-323979v1.41","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13150"},{"key":"2021090710201303000_gutjnl-2020-323979v1.42","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-13-458"},{"key":"2021090710201303000_gutjnl-2020-323979v1.43","article-title":"Durability of Nucleos(t)ide Analogues Treatment in Patients With Chronic Hepatitis B","volume":"94","author":"Lee","year":"2015","journal-title":"Medicine"},{"key":"2021090710201303000_gutjnl-2020-323979v1.44","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00705-011-1163-0","article-title":"A prospective clinical study in hepatitis B E antigen-negative chronic hepatitis B patients with stringent cessation criteria for adefovir","volume":"157","author":"Ha","year":"2012","journal-title":"Arch Virol"},{"key":"2021090710201303000_gutjnl-2020-323979v1.45","doi-asserted-by":"crossref","first-page":"1123.e1","DOI":"10.1016\/j.cmi.2015.07.023","article-title":"Ten-Year follow-up of hepatitis B relapse after cessation of lamivudine or telbivudine treatment in chronic hepatitis B patients","volume":"21","author":"Pan","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"2021090710201303000_gutjnl-2020-323979v1.46","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2334-14-439","article-title":"Off-treatment virologic relapse and outcomes of re-treatment in chronic hepatitis B patients who achieved complete viral suppression with oral nucleos(t)ide analogs","volume":"14","author":"Sohn","year":"2014","journal-title":"BMC Infect Dis"},{"key":"2021090710201303000_gutjnl-2020-323979v1.47","doi-asserted-by":"crossref","first-page":"245","DOI":"10.4103\/1319-3767.161645","article-title":"Predictors of sustained virologic response after discontinuation of nucleos(t)ide analog treatment for chronic hepatitis B","volume":"21","author":"Peng","year":"2015","journal-title":"Saudi J Gastroenterol"},{"key":"2021090710201303000_gutjnl-2020-323979v1.48","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1111\/jgh.13728","article-title":"Serum viral load at the virological relapse predicts subsequent clinical flares in chronic hepatitis B patients off entecavir therapy","volume":"32","author":"Hsu","year":"2017","journal-title":"J Gastroenterol Hepatol"},{"key":"2021090710201303000_gutjnl-2020-323979v1.49","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/j.cgh.2015.06.002","article-title":"Association between level of hepatitis B surface antigen and relapse after entecavir therapy for chronic hepatitis B virus infection","volume":"13","author":"Chen","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2021090710201303000_gutjnl-2020-323979v1.50","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.cgh.2016.03.024","article-title":"Association Between Serum Level of Hepatitis B Surface Antigen at End of Entecavir Therapy and Risk of Relapse in E Antigen-Negative Patients","volume":"14","author":"Hsu","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2021090710201303000_gutjnl-2020-323979v1.51","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3350\/cmh.2016.0047","article-title":"Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B","volume":"22","author":"Lee","year":"2016","journal-title":"Clin Mol Hepatol"},{"key":"2021090710201303000_gutjnl-2020-323979v1.52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0222221","article-title":"Incidence and predictors of retreatment in chronic hepatitis B patients after discontinuation of entecavir or tenofovir treatment","volume":"14","author":"Ma","year":"2019","journal-title":"PLoS One"},{"key":"2021090710201303000_gutjnl-2020-323979v1.53","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26549"},{"key":"2021090710201303000_gutjnl-2020-323979v1.54","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3851\/IMP3256","article-title":"DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B","volume":"23","author":"Papatheodoridis","year":"2018","journal-title":"Antivir Ther"},{"key":"2021090710201303000_gutjnl-2020-323979v1.55","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/apt.15053","article-title":"Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir","volume":"49","author":"Kuo","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2021090710201303000_gutjnl-2020-323979v1.56","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/jvh.12851","article-title":"The incidence and predictors of HBV relapse after cessation of tenofovir therapy in chronic hepatitis B patients","volume":"25","author":"Chen","year":"2018","journal-title":"J Viral Hepat"},{"key":"2021090710201303000_gutjnl-2020-323979v1.57","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/ajg.2016.109","article-title":"Assessing the durability of Entecavir-Treated hepatitis B using quantitative HBsAg","volume":"111","author":"Wang","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"2021090710201303000_gutjnl-2020-323979v1.58","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-307237"},{"key":"2021090710201303000_gutjnl-2020-323979v1.59","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jcv.2015.05.002","article-title":"Tenofovir discontinuation after long-term viral suppression in HBeAg negative chronic hepatitis B. can HBsAg levels be useful?","volume":"68","author":"Buti","year":"2015","journal-title":"J Clin Virol"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2020-323979","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T17:22:16Z","timestamp":1631035336000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2020-323979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,7]]},"references-count":59,"alternative-id":["10.1136\/gutjnl-2020-323979"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2020-323979","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,7]]}}}